Page 218 - 2022_03-Haematologica-web

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik Schjesvold,1 Paul G. Richardson,2 Thierry Facon,3 Adriań Alegre,4 Andrew Spencer,5 Artur Jurczyszyn,6 Kazutaka Sunami,7 Laurent Frenzel,8 Chang-Ki Min,9 Sophie Guillonneau,10 Peggy L. Lin,11 Solenn Le-Guennec,12 Frank Campana,13 Helgi van de Velde,13 Samira Bensfia11 and Sara Bringhen14
1Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway; 2Dana-Farber Cancer Institute, Boston, MA, USA; 3Lille University Hospital, Lille, France; 4Hospital Universitario La Princesa & Hospital Quironsalud, Madrid, Spain; 5Department of Clinical Hematology, Alfred Health-Monash University, Melbourne, Australia; 6Department of Hematology, Jagiellonian University Medical College, Krakow, Poland; 7Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan; 8Hôpital Necker-Enfants Malades, Paris, France; 9Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of South Korea; 10Sanofi CMO, Chilly-Mazarin, France; 11Sanofi Global Oncology, Cambridge, MA, USA; 12Sanofi R&D, Vitry-sur-Seine, France; 13Sanofi R&D, Cambridge, MA, USA and 14Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
Correspondence: SARA BRINGHEN - sarabringhen@yahoo.com
Published in Haematologica 2021;106(4):1182-1187
doi:10.3324/haematol.2021.279160 ©2022 Ferrata Storti Foundation
In the article by Schjesvold et al., entitled “Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis”, which appeared in the April 2021 issue of Haematologica (volume 106, pages 1182-1187), the values entered for “Refractory status” at the bottom of Table 1 were incorrect. The authors have prepared a new, corrected version of Table 1, which is reported here. The authors apologize to the Editor and readers for their mistake. They want to underscore that the results and conclusions of the paper are unaffected by the error.
774
haematologica | 2022; 107(3)
ERRATA CORRIGE